Skip to Content
  • Rank
  • Previous Rank
  • CEO
    Ian C. Read
  • Address
    235 E. 42nd St., New York, NY 10017
  • Website

Pharmaceutical giant Pfizer spent much of 2012 still reeling from the aftermath of losing exclusivity of the cholesterol-lowering medication Lipitor in November 2011. In his annual letter to shareholders, Chairman and CEO Ian Read attributed the record operational loss of $7.4 billion to the patent expirations of popular drugs like Lipitor. By the end of Q4, the company reported a $1.8 billion (or 33%) loss in primary care revenues due to patent expirations. The blow was somewhat softened by the success of drugs like Lyrica, Celebrex and Viagra, bringing the primary care unit revenues to only a slightly better 28% decrease in Q4 compared to the same time in 2011. But it hasn’t been all bad news for Pfizer. The company continued to re-structure its business strategy with the sale of its nutrition unit to Nestle and the recent IPO of the company’s stand-alone animal health business, Zoetis.

Key Financials

$ Millions% change
Total Shareholder Equity81,260-
Market Value (on March 29, 2013)207,476.3-

Profit as a % of

Profit Percent Sales207,476.3
Profit Percent Assets7.8
Profit Percent Shareholder Equity17.9

Earnings Per Share

Earnings Per Share1.94
EPS % Change (from 2012)52.8
EPS Change (5 year)10.6
EPS Change (10 year)2.9

Total Return to Investors

Total Return to Investors20.4
Total Return to Investors (5 year)7.1
Total Return to Investors (10 year)